PolyActiva Announces Positive Phase IIa Trial Results in Low Dose Cohort for PA5108 Ocular Implant with Prezia™ Sustained Drug Delivery Technology
- Written by PR Newswire
- Primary and Secondary Efficacy Endpoints Met, Demonstrating Statistically
- Significant Reduction in Intra-Ocular Pressure (IOP) for Patients with Glaucoma
MELBOURNE, Australia, Feb. 18, 2022 /PRNewswire/ -- PolyActiva Pty Ltd, a clinical-stage Australian biopharmaceutical company focused on developing unique biodegradable ocular...
